RETREG1

Across TCGA pan-cancer cohorts, RETREG1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RETREG1 data layer compared with 20 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RETREG1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RETREG1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

GBM, PDAC, and CCRCC are the cancer types where RETREG1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.274	0.474	.002	26	view →
PDAC	DFS	Median	All	0.749	0.471	.031	8	view →
CCRCC	OS	Median	II,III,IV	0.985	0.104	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RETREG1–GBM (OS)

Open the GBM breakdown →